What is Evoke Pharma?
Evoke Pharma is a specialty pharmaceutical company dedicated to the commercialization and development of therapeutics targeting gastrointestinal (GI) disorders and diseases. The company's lead product candidate is GIMOTI, a nasal spray formulation of metoclopramide, designed to alleviate symptoms associated with acute and recurrent diabetic gastroparesis in adult patients. This focus positions Evoke Pharma within a critical niche of the healthcare market, addressing unmet needs in digestive health.
How much funding has Evoke Pharma raised?
Evoke Pharma has raised a total of $28.7M across 2 funding rounds:
Stock Offering
$25.2M
Stock Offering
$3.5M
Stock Issuance/Offering (2013): $25.2M, investors not publicly disclosed
Stock Issuance/Offering (2024): $3.5M, investors not publicly disclosed
What's next for Evoke Pharma?
The recent major strategic investment signals a pivotal moment for Evoke Pharma, likely enabling the company to accelerate its commercialization efforts for GIMOTI and potentially expand its development pipeline. This infusion of capital is expected to fuel growth initiatives, enhance market penetration, and support ongoing research and development activities. The enterprise-level funding context suggests a strategic phase focused on scaling operations and solidifying its market presence in the competitive pharmaceutical landscape.
See full Evoke Pharma company page
